Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
Affimed needs more time with AFM24
Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
ESMO 2024 – J&J eyes Rybrevant colorectal expansion
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
World Lung 2024 – ArriVent looks for lung cancer white space
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
